DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Description
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
Eligibility
See official grant page for eligibility requirements
Industry Tags
About This Grant
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
Funding Information
- Estimated Total Program Funding
- $5,600,000
- Expected Number of Awards
- 2
Eligibility Overview
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.
Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:
- Nonprofits and 501(c)(3) organizations
- Small businesses and startups (especially for SBIR/STTR programs)
- State, local, and tribal governments
- Colleges, universities, and research institutions
- Individuals (for select programs in education, arts, and research)
Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.
How to Apply
- 1
Review the full opportunity
Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362195).
- 2
Confirm eligibility
Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.
- 3
Prepare required documents
Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.
- 4
Submit before the deadline
This opportunity closes on September 30, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.
Grant Writing Tips
Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:
- ✓Start your application at least 4 weeks before the deadline — rushed proposals score lower.
- ✓Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
- ✓Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.
More Grants from Defense Health Agency Contracting Activity - DHACA
Frequently Asked Questions
Who is eligible for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award?
This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.
How much funding does DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award provide?
The total estimated program funding for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award is $5,600,000.
When is the deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award?
The application deadline for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award is September 30, 2026. Submit at least 48 hours early to avoid last-minute portal issues.
How do I apply for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award?
Apply for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award through the official grant page (https://www.grants.gov/search-results-detail/362195). Confirm your eligibility and prepare your application materials before the deadline.
Helpful Resources
Need help writing your grant application?
Try Instrumentl — Grant Writing Software →Starting a nonprofit to apply for grants?
Launch your nonprofit with Swyft Filings →GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.